CTOs on the Move

Art and Drama Therapy Institute

www.adtinet.com

 
Art and Drama Therapy Institute is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

cbdMD

Discover our THC-free, superior CBD products. Featuring award-winning, high-quality hemp oil. Feel & taste the difference. Visit to learn more.

Mirth Corporation

Mirth Corporation is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Back in Motion Rehab

Back in Motion is the British Columbia leader in rehabilitation, disability prevention and employment solutions. Since 1993, BiM has provided quality innovative solutions to workers, employers and job seekers, as well as to program funders. We have grown to over 200 employees and contractors, and presently deliver rehabilitation, assessment, and employment programs and services in Richmond, Surrey (Newton), Surrey (Panorama), Vancouver, Coquitlam, Port Coquitlam, and Langley. Back in Motion has received recognition as an excellent workplace (Great Place to Work Institute Canada 2006-2008, including being named the #1 workplace in Canada in 2007; Psychologically Healthy Workplace Award 2009; Richmond News Profile of Excellence 2013).

Joy Medical Group

Joy Medical Group is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.